Search clinical trials for: Combination+of+Bendamustine+%2B+Dasatinib

Total 6128 results

Bristol-Myers Squibb

Withdrawn

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
University Hospital Tuebingen
Arbeitsgemeinschaft fur Internistische Onkologie; German Sarcoma Group

Completed

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Sarcoma, Soft Tissue

Germany
Charite University, Berlin, Germany
ribosepharm GmbH

Unknown

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
St. Petersburg State Pavlov Medical University
N.N. Petrov National Medical Research Center of Oncology

Recruiting

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma (Prolgo-HL)

Hodgkin Lymphoma

Russian Federation
Bristol-Myers Squibb

Withdrawn

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

United States
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
Medical University of Vienna

Not yet recruiting

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Mantle-cell Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
TG Therapeutics, Inc.

Terminated

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

B-cell Non Hodgkin Lymphoma | Richter's Transformation

United States
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Beth Christian

Completed

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Meir Medical Center
Assuta Ashdod Hospital; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Ziv Medical Center

Recruiting

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)

Follicular Lymphoma

Israel
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
Novartis Pharmaceuticals

Completed

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Neoplasms, Breast

Canada, Netherlands, United States, Spain, Korea, Republic of
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
Yonsei University

Completed

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NSCLC
Cyteir Therapeutics, Inc.

Active, not recruiting

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Soft Tissue Sarcoma | Follicular Lymphoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Multiple Myeloma | Pancreatic Cancer | Ovarian Cancer | Mantle Cell Lymphoma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | DLBCL | Non-hodgkin Lymphoma | Malignancy | CLL

United States
Qin Ning

Unknown

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV)

Chronic Hepatitis b
University of Alabama at Birmingham
GlaxoSmithKline; AbbVie; Breast Cancer Research Foundation of Alabama

Active, not recruiting

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
University of Arizona
Cephalon

Completed

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Ovarian Cancer

United States
Boehringer Ingelheim

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Breast Neoplasms

United States, Brazil, Colombia, Peru
Peking Union Medical College Hospital

Recruiting

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Radioactive Iodine-refractory Differentiated Thyroid Cancer

China
Bristol-Myers Squibb

Completed

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Pharmacokinetic Study in Healthy Participants

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Aptevo Therapeutics

Completed

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States, Austria, Germany, Poland, Spain
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Fujian Medical University

Completed

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Neoadjuvant Therapy | Advanced Gastric Cancer | Multi-omics Analysis

China
Merck Sharp & Dohme LLC

Completed

Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (Pegade)

Hepatitis C, Chronic
NYU Langone Health
Cephalon

Terminated

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Withdrawn

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Lymphoma | Leukemia
University of Washington
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
Southern Europe New Drug Organization
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Unknown

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Lymphoma, Mantle-Cell

Italy
M.D. Anderson Cancer Center
Cephalon

Terminated

Bendamustine in Acute Leukemia and MDS

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Spectrum Health Hospitals

Completed

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Georg Hess, MD
Wyeth is now a wholly owned subsidiary of Pfizer; Mundipharma Pte Ltd.

Completed

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (BERT)

Follicular Lymphoma | Mantle Cell Lymphoma

Germany
Hyoung Jin Kang

Not yet recruiting

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea (VHR ALL)

Acute Lymphoblastic Leukemia, Pediatric
Georgetown University
GlaxoSmithKline; Cephalon

Terminated

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
Prof. Dr. Wolfgang Hiddemann
Hoffmann-La Roche; Mundipharma Research GmbH & Co KG

Completed

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years (GABe2016)

Indolent Non-hodgkin Lymphoma

Germany
Cephalon

Completed

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Malignancy

Netherlands

Search clinical trials for: Combination+of+Bendamustine+%2B+Dasatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations